Combination therapy with conditionally replicating adenovirus and replication defective adenovirus

Cancer Research
Choon-Taek LeeD P Carbone

Abstract

Low gene transfer rate is the most substantial hurdle in the practical application of gene therapy. One strategy to improve transfer efficiency is the use of a conditionally replicating adenovirus (CRAD) that can selectively replicate in tumor cells. We hypothesized that conventional E1-deleted adenoviruses (ad) can become replication-competent when cotransduced with a CRAD to selectively supply E1 in trans in tumors. The resulting selective production of large numbers of the E1-deleted ad within the tumor mass will increase the transduction efficiency. We used a CRAD (Delta24RGD) that produces a mutant E1 without the ability to bind retinoblastoma but retaining viral replication competence in cancer cells with a defective pRb/p16. Ad-lacZ, adenovirus-luciferase (ad-luc), and adenovirus insulin-like growth factor-1R/dominant-negative (ad-IGF-1R/dn; 482, 950) are E1-deleted replication-defective adenoviruses. The combination of CRAD and ad-lacZ increased the transduction efficiency of lacZ to 100% from 15% observed with ad-lacZ alone. Transfer of media of CRAD and ad-lacZ cotransduced cells induced the transfer of lacZ (media transferable bystander effect). Combination of CRAD and ad-IGF-1R/dn increased the production of truncat...Continue Reading

References

Mar 22, 2002·The Lancet Oncology·Lynda K HawkinsDavid Kirn
Jan 11, 2003·Cancer Gene Therapy·Tony ReidDavid Kirn
May 3, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Maxine BauzonTerry W Hermiston
Jul 15, 2003·Gene Therapy·T-G HuangS L C Woo
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qian HuangChuan-Yuan Li

❮ Previous
Next ❯

Citations

Jul 1, 2011·Immunologic Research·Steve H Thorne
May 26, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Huiping WangQian Huang
Oct 26, 2007·The Journal of Investigative Dermatology·Dennis HoffmannOliver Wildner
Jan 24, 2007·Thoracic Surgery Clinics·Eric M Toloza
Mar 15, 2008·International Journal of Cancer. Journal International Du Cancer·Masayoshi HiokiToshiyoshi Fujiwara
Aug 30, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Tamotsu SagawaYoshiro Niitsu
Mar 1, 2012·International Journal of Cancer. Journal International Du Cancer·Seung Hyun OhHo-Young Lee
Dec 1, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yoon-Jin LeeChoon-Taek Lee
Sep 1, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Noriko MotoiKunihiko Yoshimura
Oct 31, 2006·The American Journal of Pathology·Hae-June LeeYun-Sil Lee
Oct 2, 2012·Virology·Jorge G Gomez-GutierrezKelly M McMasters
Jun 19, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Valentina HoyosMalcolm K Brenner
Feb 14, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Stephen H ThorneCalvin J Kuo
Jun 13, 2006·Journal of Cellular Biochemistry·Eric M TolozaH Kim Lyerly
Nov 19, 2020·Cancers·Malin Peter, Florian Kühnel

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.